The glycomic profile of invasive ductal carcinoma of the breast is altered in patients with hypoxic regions: Implications for tumor behavior

Folia Histochemica et Cytobiologica

Volumn 52, Issue 2, 2014, Pages 96-103

  Rêgo, Moacyr Jesus Barreto de Melo ^a   Filho, Antônio Felix da Silva ^a   Cordeiro, Marina Ferraz ^a   Santos, Petra Barros ^a   Beltrão, Eduardo Isidoro Carneiro ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Breast cancer; Galectins; Glycomic profile; Histochemistry; Hypoxia; IDC; IHC; Lectin ligands

Indexed keywords

CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GALECTIN 1; GALECTIN 3; GLYCAN; HYPOXIA INDUCIBLE FACTOR; PHYTOHEMAGGLUTININ; PROGESTERONE RECEPTOR; SIALIC ACID; CARBONATE DEHYDRATASE; ERBB2 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CARBOHYDRATE ANALYSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GLYCOBIOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE CONTROL STUDY; CELL HYPOXIA; FEMALE; GENETICS; METABOLISM;

ADULT; BREAST NEOPLASMS; CARBONIC ANHYDRASES; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CELL HYPOXIA; FEMALE; GALECTIN 1; GALECTIN 3; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OXYGEN; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904101587     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2014.0017     Document Type: Article

References (44)

1. DeSantis C, Ma J, Bryan L et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64: 52-62.
2. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. 2009; 107: 1053-1062.
3. Moeller B, J Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007; 26: 241-248.
4. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem. 2008; 8: 790-797.
5. Adams JM, Difazio LT, Rolandelli RH et al. HIF-1: a key mediator in hypoxia. Acta Physiol Hung. 2009; 96: 19-28.
6. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 310: 721-732.
7. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther. 2004; 3: 647-654.
8. Shirato K, Nakajima K, Korekane H et al. Hypoxic regulation of glycosylation via the N-acetylglucosamine cycle. J Clin Biochem Nutr. 2008; 48: 20-25.
9. Taniguchi N. From the gamma-glutamyl cycle to the glycan cycle: a road with many turns and pleasant surprises. J Biol Chem. 2009; 11: 34469-34478.
10. Olbryt M, Jarzab M, Jazowiecka-Rakus J et al. Gene expression profile of B 16(F10) murine melanoma cells exposed to hypoxic conditions in vitro. Gene Expr. 2006; 13: 191-203.
11. Zeng Y, Danielson KG, Albert TJ et al. HIF-1 alpha is a regulator of galectin-3 expression in the intervertebral disc. J Bone Mines Res. 2007; 22: 1851-1861.
12. Rego MJBM, Melo GSV, Santos CAS et al. Implications on glycobiological aspects of tumor hypoxia in breast ductal carcinoma in situ. Med Molec Morphol. 2013; 46: 92-96.
13. Sobral APV, Rego MJBM, Cavalcanti CLB et al. Con A and UEA-I lectin histochemistry of parotid gland mucoepidermoid carcinoma. J Oral Sci. 2010; 52: 49-54.
14. Dos Santos P, Zanetti JS, Alfredo RS et al. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol. 2012; 7: 104.
15. Allred DC, Harvey JM, Berardo M et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11: 155-168.
16. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendation for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-145.
17. Zanetti JS, Soave DF, Costa JPO et al. The role of tumor hypoxia in MUC1-positive breast carcinomas. Virchows Arch. 2011; 459: 367-375.
18. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
19. Sundblad V, Croci DO, Rabinovich GA. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol Histopathol. 2011; 26: 247-265.
20. Robertson N, Potter C, Harris AL et al. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004; 64: 6160-6165.
21. Shareef MM, Udayakumar TS, Sinha VK et al. Interaction of HIF-1a and Notch3 is required for the expression of carbonic anhydrase 9 in breast carcinoma cells. Genes & Cancer. 2013; 4: 11-12.
22. Kaya AO, Gunel N, Benekli M et al. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. J BUON. 2012; 17: 663-668.
23. Furjelováa M, Kovalskáa M, Jurková K et al. Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma. Acta Histochem. 2014; 116: 89-93.
24. Tan EY, Yan M, Campo L et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer. 2009; 100: 405-411.
25. Chaudary N, Hill RP. Hypoxia and metastasis in breast cancer. Breast Dis. 2007; 26: 55-64.
26. Brennan DJ, Jirstrom K, Kronblad A et al. CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clin Cancer Res. 2006; 12: 6421-6431.
27. Chia BSK, Wykoff CC, Watson PH et al. Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma. J Clin. Oncol. 2001; 19: 3660-3668.
28. Generali D, Fox SB, Berruti A et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer. 2006; 13: 921-930.
29. Lou Y, Mcdonald PC, Oloumi A et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Rev. 2011; 171: 3364-3376.
30. Agurs-Collins T, Dunn BK, Browne D et al. Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. Semin Oncol. 2010; 37: 384-401.
31. Ryu K, Park C, Joo-lee Y. Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells. Biochem Biophys Res Commun. 2011; 407: 831-836.
32. Jung TY, Jung S, Ryu, HH et al. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg. 2008; 109: 273-284.
33. Le QT, Shi G, Cao H et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005; 23: 8932-8941.
34. Ito K, Stannard K, Gabutero E. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev. 2012; 31: 763-778.
35. Moisa A, Fritz P, Eck A. Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res. 2007; 27: 2131-2139.
36. Castronovo V, Van Den Brule FA, Jackers P. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol. 1996; 179: 43-48.
37. Shekhar MP, Nangia-Makker P, Tait L et al. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 2004; 165: 1931-1941.
38. Song S, Mazurek N, Liu C et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009; 69: 1343-1349.
39. Ikemori RY, Machado CML, Nonogaki S, Verinaud L, Chammas R. Hypoxia-induced galectin-3 plays a role in the survival of nutrient deprived glioblastoma cells. In: Annual Meeting of the Society for Glycobiology, 2009, San Diego. Glycobiology (Oxford), 2009; 19: 1318. Available at: http: // glycob.oxfordjournals.org/content/19/11/1259.full.pdf+html.
40. Balan V, Nangia-makker P, Jung YS et al. Galectin-3: A novel substrate for c-Abl kinase. Biochim Biophys Acta. 2010; 1803: 1198-1205.
41. Ochieng J, Green B, Evans S et al. Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta. 1998; 1379: 97-106.
42. Wang Y, Ao X, Vuong H. Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res. 2008; 10: 4313-4325.
43. Chi-long C, Chu J, Su W et al. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1a, GLUT1, and CAIX. Virchows Arch. 2010; 457: 53-61.
44. Suzuki O, Nozawa Y, Kawaguchi T et al. Alpha-2, 6-sialylation of L-PHA reactive oligosaccharides and expression of N-acetylglucosaminyltransferase V in human diffuse large B cell lymphoma. Oncol Rep. 2003; 10: 1759-1764.